세계의 조직공학 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Tissue Engineering was estimated to be worth US$ 4312 million in 2024 and is forecast to a readjusted size of US$ 11983 million by 2031 with a CAGR of 15.2% during the forecast period 2025-2031.

Tissue Engineering is an interdisciplinary field that integrates cell biology, materials science, engineering, and clinical medicine, aiming to construct functional tissues or organs in vitro to replace, repair, or enhance damaged or degenerated human tissues. Its foundation lies in the combination of seed cells, scaffold materials, and bioactive factors under a simulated physiological environment to guide cell proliferation, differentiation, and tissue regeneration. Currently, tissue engineering is demonstrating strong application potential in areas such as skin regeneration, bone repair, cartilage reconstruction, cardiovascular repair, and organ replacement, making it a core technology in regenerative medicine and precision therapy.

With the global aging population, rising prevalence of chronic diseases, and the persistent imbalance between organ transplant demand and supply, tissue engineering is emerging as a crucial solution to major clinical challenges. Governments and healthcare systems worldwide are investing heavily in regenerative medicine, accelerating the clinical translation of tissue engineering. Continuous breakthroughs in supporting technologies-such as biomaterials, stem cells, and 3D bioprinting-have enhanced product performance and scalability, expanding commercialization prospects. Cross-sector collaborations among hospitals, research institutions, and biotech firms are intensifying, propelling the transition from lab to clinic.

Despite the immense potential, the tissue engineering market faces considerable challenges. Issues such as biocompatibility, immune rejection, long clinical trial timelines, and unclear regulatory pathways hinder large-scale commercialization. High R&D costs, technological complexity, and underdeveloped business models make it difficult for smaller firms to sustain operations. Moreover, strict regulatory and ethical frameworks across countries add additional layers of complexity to product design, testing, and market entry.

The current downstream demand is concentrated in skin regeneration, bone repair, oral and maxillofacial surgery, and cardiovascular applications. In the future, the market is expected to expand into more complex organ replacements, such as liver and kidney engineering. Emerging platform technologies like 3D bioprinting and organ-on-a-chip are enabling personalized and customized solutions, becoming new growth drivers. Furthermore, the use of engineered tissues in drug screening and toxicology assessments is rapidly growing, steadily expanding the research-use market. Hospitals, CROs, biopharmaceutical companies, and medtech enterprises are all actively extending the clinical value chain of tissue engineering products.

This report aims to provide a comprehensive presentation of the global market for Tissue Engineering, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Tissue Engineering by region & country, by Type, and by Application.

The Tissue Engineering market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tissue Engineering.

Market Segmentation

By Company

• AbbVie
• Integra Lifesciences
• BD
• Zimmer Biomet
• Organogenesis
• Osiris Therapeutics
• Medtronic
• Smith & Nephew
• Cytograft Tissue Engineering
• MiMedx Group
• Episkin
• J-TEC
• 3M
• Biotime
• B. Braun
• International Stem Cell
• Vericel Corporation

Segment by Type

• Synthetic Materials
• Biologically Derived Materials
• Others

Segment by Application

• Neurology
• Cardiology and Vascular
• Skin and Integumentary
• Orthopedics, Musculoskeletal and Spine
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Tissue Engineering company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Tissue Engineering in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Tissue Engineering in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Tissue Engineering Product Introduction
• 1.2 Global Tissue Engineering Market Size Forecast (2020-2031)
• 1.3 Tissue Engineering Market Trends & Drivers
  • 1.3.1 Tissue Engineering Industry Trends
  • 1.3.2 Tissue Engineering Market Drivers & Opportunity
  • 1.3.3 Tissue Engineering Market Challenges
  • 1.3.4 Tissue Engineering Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Tissue Engineering Players Revenue Ranking (2024)
• 2.2 Global Tissue Engineering Revenue by Company (2020-2025)
• 2.3 Key Companies Tissue Engineering Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Tissue Engineering Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Tissue Engineering
• 2.6 Tissue Engineering Market Competitive Analysis
  • 2.6.1 Tissue Engineering Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Tissue Engineering Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tissue Engineering as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Synthetic Materials
  • 3.1.2 Biologically Derived Materials
  • 3.1.3 Others
• 3.2 Global Tissue Engineering Sales Value by Type
  • 3.2.1 Global Tissue Engineering Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Tissue Engineering Sales Value, by Type (2020-2031)
  • 3.2.3 Global Tissue Engineering Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Neurology
  • 4.1.2 Cardiology and Vascular
  • 4.1.3 Skin and Integumentary
  • 4.1.4 Orthopedics, Musculoskeletal and Spine
  • 4.1.5 Others
• 4.2 Global Tissue Engineering Sales Value by Application
  • 4.2.1 Global Tissue Engineering Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Tissue Engineering Sales Value, by Application (2020-2031)
  • 4.2.3 Global Tissue Engineering Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Tissue Engineering Sales Value by Region
  • 5.1.1 Global Tissue Engineering Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Tissue Engineering Sales Value by Region (2020-2025)
  • 5.1.3 Global Tissue Engineering Sales Value by Region (2026-2031)
  • 5.1.4 Global Tissue Engineering Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Tissue Engineering Sales Value, 2020-2031
  • 5.2.2 North America Tissue Engineering Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Tissue Engineering Sales Value, 2020-2031
  • 5.3.2 Europe Tissue Engineering Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Tissue Engineering Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Tissue Engineering Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Tissue Engineering Sales Value, 2020-2031
  • 5.5.2 South America Tissue Engineering Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Tissue Engineering Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Tissue Engineering Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Tissue Engineering Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Tissue Engineering Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Tissue Engineering Sales Value, 2020-2031
  • 6.3.2 United States Tissue Engineering Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Tissue Engineering Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Tissue Engineering Sales Value, 2020-2031
  • 6.4.2 Europe Tissue Engineering Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Tissue Engineering Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Tissue Engineering Sales Value, 2020-2031
  • 6.5.2 China Tissue Engineering Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Tissue Engineering Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Tissue Engineering Sales Value, 2020-2031
  • 6.6.2 Japan Tissue Engineering Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Tissue Engineering Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Tissue Engineering Sales Value, 2020-2031
  • 6.7.2 South Korea Tissue Engineering Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Tissue Engineering Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Tissue Engineering Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Tissue Engineering Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Tissue Engineering Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Tissue Engineering Sales Value, 2020-2031
  • 6.9.2 India Tissue Engineering Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Tissue Engineering Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 AbbVie
  • 7.1.1 AbbVie Profile
  • 7.1.2 AbbVie Main Business
  • 7.1.3 AbbVie Tissue Engineering Products, Services and Solutions
  • 7.1.4 AbbVie Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.1.5 AbbVie Recent Developments
• 7.2 Integra Lifesciences
  • 7.2.1 Integra Lifesciences Profile
  • 7.2.2 Integra Lifesciences Main Business
  • 7.2.3 Integra Lifesciences Tissue Engineering Products, Services and Solutions
  • 7.2.4 Integra Lifesciences Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Integra Lifesciences Recent Developments
• 7.3 BD
  • 7.3.1 BD Profile
  • 7.3.2 BD Main Business
  • 7.3.3 BD Tissue Engineering Products, Services and Solutions
  • 7.3.4 BD Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.3.5 BD Recent Developments
• 7.4 Zimmer Biomet
  • 7.4.1 Zimmer Biomet Profile
  • 7.4.2 Zimmer Biomet Main Business
  • 7.4.3 Zimmer Biomet Tissue Engineering Products, Services and Solutions
  • 7.4.4 Zimmer Biomet Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Zimmer Biomet Recent Developments
• 7.5 Organogenesis
  • 7.5.1 Organogenesis Profile
  • 7.5.2 Organogenesis Main Business
  • 7.5.3 Organogenesis Tissue Engineering Products, Services and Solutions
  • 7.5.4 Organogenesis Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Organogenesis Recent Developments
• 7.6 Osiris Therapeutics
  • 7.6.1 Osiris Therapeutics Profile
  • 7.6.2 Osiris Therapeutics Main Business
  • 7.6.3 Osiris Therapeutics Tissue Engineering Products, Services and Solutions
  • 7.6.4 Osiris Therapeutics Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Osiris Therapeutics Recent Developments
• 7.7 Medtronic
  • 7.7.1 Medtronic Profile
  • 7.7.2 Medtronic Main Business
  • 7.7.3 Medtronic Tissue Engineering Products, Services and Solutions
  • 7.7.4 Medtronic Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Medtronic Recent Developments
• 7.8 Smith & Nephew
  • 7.8.1 Smith & Nephew Profile
  • 7.8.2 Smith & Nephew Main Business
  • 7.8.3 Smith & Nephew Tissue Engineering Products, Services and Solutions
  • 7.8.4 Smith & Nephew Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Smith & Nephew Recent Developments
• 7.9 Cytograft Tissue Engineering
  • 7.9.1 Cytograft Tissue Engineering Profile
  • 7.9.2 Cytograft Tissue Engineering Main Business
  • 7.9.3 Cytograft Tissue Engineering Tissue Engineering Products, Services and Solutions
  • 7.9.4 Cytograft Tissue Engineering Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Cytograft Tissue Engineering Recent Developments
• 7.10 MiMedx Group
  • 7.10.1 MiMedx Group Profile
  • 7.10.2 MiMedx Group Main Business
  • 7.10.3 MiMedx Group Tissue Engineering Products, Services and Solutions
  • 7.10.4 MiMedx Group Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.10.5 MiMedx Group Recent Developments
• 7.11 Episkin
  • 7.11.1 Episkin Profile
  • 7.11.2 Episkin Main Business
  • 7.11.3 Episkin Tissue Engineering Products, Services and Solutions
  • 7.11.4 Episkin Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Episkin Recent Developments
• 7.12 J-TEC
  • 7.12.1 J-TEC Profile
  • 7.12.2 J-TEC Main Business
  • 7.12.3 J-TEC Tissue Engineering Products, Services and Solutions
  • 7.12.4 J-TEC Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.12.5 J-TEC Recent Developments
• 7.13 3M
  • 7.13.1 3M Profile
  • 7.13.2 3M Main Business
  • 7.13.3 3M Tissue Engineering Products, Services and Solutions
  • 7.13.4 3M Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.13.5 3M Recent Developments
• 7.14 Biotime
  • 7.14.1 Biotime Profile
  • 7.14.2 Biotime Main Business
  • 7.14.3 Biotime Tissue Engineering Products, Services and Solutions
  • 7.14.4 Biotime Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Biotime Recent Developments
• 7.15 B. Braun
  • 7.15.1 B. Braun Profile
  • 7.15.2 B. Braun Main Business
  • 7.15.3 B. Braun Tissue Engineering Products, Services and Solutions
  • 7.15.4 B. Braun Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.15.5 B. Braun Recent Developments
• 7.16 International Stem Cell
  • 7.16.1 International Stem Cell Profile
  • 7.16.2 International Stem Cell Main Business
  • 7.16.3 International Stem Cell Tissue Engineering Products, Services and Solutions
  • 7.16.4 International Stem Cell Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.16.5 International Stem Cell Recent Developments
• 7.17 Vericel Corporation
  • 7.17.1 Vericel Corporation Profile
  • 7.17.2 Vericel Corporation Main Business
  • 7.17.3 Vericel Corporation Tissue Engineering Products, Services and Solutions
  • 7.17.4 Vericel Corporation Tissue Engineering Revenue (US$ Million) & (2020-2025)
  • 7.17.5 Vericel Corporation Recent Developments

8 Industry Chain Analysis

• 8.1 Tissue Engineering Industrial Chain
• 8.2 Tissue Engineering Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Tissue Engineering Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Tissue Engineering Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer